Table 1.
Consented to PG sampling (n = 1674) |
Did not consent to PG sampling (n = 1275) |
P | |
---|---|---|---|
Gender, n (%) | 0.04 | ||
Male | 1021 (58) | 729 (42) | |
Female | 653 (54) | 546 (46) | |
Race, n (%) | 0.07 | ||
White | 1214 (58) | 882 (42) | |
African American | 293 (54) | 254 (46) | |
Hispanic | 121 (57) | 90 (43) | |
Asian | 21 (41) | 30 (59) | |
Other | 25 (57) | 19 (43) | |
Age, y, mean (SD) | 47.4 (7.9) | 47.6 (8.3) | 0.71 |
Baseline HCV RNA, n (%) | 0.17 | ||
>600,000 IU/mL | 1388 (57) | 1032 (43) | |
≤600,000 IU/mL | 286 (54) | 243 (46) | |
METAVIR fibrosis score, n (%)* | 0.7 | ||
F0 | 25 (54) | 21 (46) | |
F1 | 1160 (58) | 857 (42) | |
F2 | 235 (55) | 192 (45) | |
F3 | 66 (55) | 54 (45) | |
F4 | 112 (58) | 80 (42) | |
Baseline smoking history, n (%)† | 0.39 | ||
Current smoker | 620 (57) | 470 (43) | |
Ex-smoker | 626 (58) | 455 (42) | |
Non-smoker | 390 (54) | 327 (46) | |
History of alcohol abuse, n (%) | 153 (58) | 109 (42) | 0.58 |
History of depression, n (%) | 391 (57) | 299 (43) | 0.95 |
History of diabetes, n (%) | 112 (57) | 85 (43) | 0.98 |
History of hypertension, n (%) | 454 (57) | 342 (43) | 0.86 |
History of coronary artery disease, n (%) | 25 (57) | 19 (43) | 0.99 |
Missing 76 of those who participated in pharmacogenomic testing and 71 of those who did not.
Missing 38 of those who participated in pharmacogenomic testing and 23 of those who did not.
Abbreviations: PG, pharmacogenomics testing.